NOT FOR DISSEMINATION IN THE UNITED STATES OF AMERICA

VentriPoint Diagnostics Ltd. (the "Corporation") (TSX VENTURE:VPT) has today
made the significant announcement that its wholly-owned subsidiary, VentriPoint,
Inc. ("VentriPoint") has been granted a medical device license by Health Canada
to sell and market its VentriPoint Medical System ("VMS") to provide key
measurements and accurate reconstructions of the right ventricle of a patient's
heart from standard two-dimensional ultrasound images.


"This regulatory milestone is a major advancement in VentriPoint's efforts to
provide cost effective monitoring and treatment for patients with heart disease.
Having achieved this milestone VentriPoint can proceed with its
commercialization plans to introduce the VMS diagnostic tool for Canada's
congenital heart disease population and to advance its use for other heart
diseases, including pulmonary hypertension," stated Joe Ashley, President & CEO
of the Corporation. "The availability of the VMS to quickly and inexpensively
provide critical information of a patient's right ventricle is expected to help
enable Canadian healthcare organizations to better monitor and treat patients
suffering from heart disease."


Concurrently, VentriPoint also announced today that its Quality Management
System, which covers the design and development of its VMS, has met the
requirements of the ISO 13485:2003 standard. This certification was obtained
following a successful audit in January 2009 by Intertek Testing Services NA
Ltd. This certification is an internationally recognized management system
standard developed by the International Organization for Standardization (ISO).
"The certification is an important measure of the Company's quality
capabilities. ISO certification is another significant achievement for
VentriPoint and reflects our commitment to excellent performance in our internal
design and manufacture of the VMS," said Scott Ashley, Vice President of
Research & Development. "Our proven quality management system will facilitate
regulatory approvals of our products on a global basis."


About VentriPoint Diagnostics Ltd. 

VentriPoint creates diagnostic tools to monitor patients with heart disease -
the number one cause of death in developed countries. By using images produced
from existing medical imaging systems, the VentriPoint Medical System ("VMS")
generates critical heart measurements in a rapid and inexpensive manner not
currently available. Health Canada has granted licensed approval for the VMS
breakthrough diagnostic tool which is based upon technology received by
VentriPoint through its exclusive technology license with the University of
Washington. The VMS, together with its associated online service, is being
expanded to cover a variety of heart related disease states, including
congenital heart disease.


To receive press release, please email chris@chfir.com and mention VentriPoint
in the subject line.


FORWARD-LOOKING STATEMENTS: The statements made in this press release that are
not historical facts contain forward-looking information that involves risk and
uncertainties. All statements, other than statements of historical facts, which
address VentriPoint's expectations, should be considered forward-looking
statements. Such statements are based on management's exercise of business
judgment as well as assumptions made by and information currently available to
management. When used in this document, the words "may", "will", "anticipate",
"believe", "estimate", "expect", "intend" and words of similar import, are
intended to identify any forward-looking statements. You should not place undue
reliance on these forward-looking statements. These statements reflect a current
view of future events and are subject to certain risks and uncertainties as
contained in the Corporations filings with Canadian securities regulatory
authorities. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results could differ
materially from those anticipated in these forward-looking statements. The
Corporation undertakes no obligation, and does not intend, to update, revise or
otherwise publicly release any revisions to these forward-looking statements to
reflect events or circumstances after the date hereof, or to reflect the
occurrence of any unanticipated events. Although management believes that
expectations are based on reasonable assumptions, no assurance can be given that
these expectations will materialize.
Vortex Metals (TSXV:VMS)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Vortex Metals Charts.
Vortex Metals (TSXV:VMS)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Vortex Metals Charts.